News archive

Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia

Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus

Johnson & Johnson partially converts its convertible loan

Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway

Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease

Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd

Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company

Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

Idorsia holds its Annual General Meeting of Shareholders

Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway

Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders

The European Medicines Agency’s CHMP issues a positive opinion recommending marketing authorisation for Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis

US FDA approves Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis

FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia

Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia

Idorsia submits NDA for clazosentan to Japanese PMDA